Prescient Therapeutics (FRA:UDD) Construction In Progress: €0.00 Mil (As of Dec. 2025)


FRA:UDD Prescient Therapeutics Ltd FRA:UDD
22 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Prescient Therapeutics Construction In Progress?

Prescient Therapeutics FRA:UDD +1.64% 22 Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:UDD with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Prescient Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Construction In Progress Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:UDD
22GF Score
Prescient Therapeutics Ltd FRA:UDD
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prescient Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Prescient Therapeutics (FRA:UDD) has a Construction In Progress of €0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Construction In Progress too high?
Prescient Therapeutics' current Construction In Progress is €0.00 Mil. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' Construction In Progress compare to VRTX and REGN?
Prescient Therapeutics' Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Construction In Progress of €0.00 Mil. The current Construction In Progress is €0.00 Mil. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Construction In Progress is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score

Get the complete analysis for FRA:UDD

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price